Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post
Abiraterone | Uses, Brand Names, Mechanism Of Action
Abiraterone Acetate API Manufacturer and Supplier | CAS 154229-18-2 - Dr. Reddy's
Mechanism of Action of Abiraterone Acetate 7 | Download Scientific Diagram
Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
Abiraterone Acetate - an overview | ScienceDirect Topics
Abiraterone acetate for the treatment of castrate-refractory prostate cancer | Aging Health
Abiraterone Acetate tablets 250mg price in India
202379Orig1s000
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer - Qin - 2018 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Oncology
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Abiraterone acetate in the treatment of prostate cancer - ScienceDirect
Abiraterone Acetate Tablets Manufacturer & Supplier India
AusPAR Attachment 1: Product Information for Zytiga (abiraterone acetate)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 ...
AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD
Abiraterone acetate in the treatment of prostate cancer - ScienceDirect
Abiraterone | C24H31NO | CID 132971 - PubChem
Cancers | Free Full-Text | Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
2011 Prostate Cancer Highlights, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD
Zytiga (Abiraterone J&J) for Treatment of Prostate Cancer (mCRPC) - Prostate Cancer Specialists in NYC
pipeline -
